Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02DDI
|
|||
| Former ID |
DNC006874
|
|||
| Drug Name |
KYS-05064
|
|||
| Synonyms |
KYS-05064; CHEMBL217660; SCHEMBL14417343; BDBM50192101; 2-(3-ethyl-2-(piperidin-1-yl)-3,4-dihydroquinazolin-4-yl)-N-(4-(4-methylphenylsulfonamido)benzyl)acetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H37N5O3S
|
|||
| Canonical SMILES |
CCN1C(C2=CC=CC=C2N=C1N3CCCCC3)CC(=O)NCC4=CC=C(C=C4)NS(=O)(=O)C5=CC=C(C=C5)C
|
|||
| InChI |
1S/C31H37N5O3S/c1-3-36-29(27-9-5-6-10-28(27)33-31(36)35-19-7-4-8-20-35)21-30(37)32-22-24-13-15-25(16-14-24)34-40(38,39)26-17-11-23(2)12-18-26/h5-6,9-18,29,34H,3-4,7-8,19-22H2,1-2H3,(H,32,37)
|
|||
| InChIKey |
AAULUGZZFCAQJP-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) | Target Info | Inhibitor | [1] |
| KEGG Pathway | MAPK signaling pathway | |||
| Calcium signaling pathway | ||||
| Circadian entrainment | ||||
| Type II diabetes mellitus | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| GABA-B receptor II signaling | ||||
| Nicotine pharmacodynamics pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| Reactome | NCAM1 interactions | |||
| WikiPathways | NCAM signaling for neurite out-growth | |||
| Nicotine Activity on Chromaffin Cells | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem. 2007 Jan 15;15(2):1091-105. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.